Ainos Provides Insights Into Its Ai Nose Technology

Ainos, Inc. is a diversified medtech company focused on the development of novel point-of-care testing, low-dose interferon therapeutics, and synthetic RNA-driven preventative medicine. The company has developed AI-powered digital nose technology, AI Nose, which consists of an array of digital nose sensors used to detect volatile organic compounds (VOCs). AI Nose utilizes deep learning and other advanced AI algorithms to accurately identify VOC samples, which can be used to detect diseases. Clinical trials of AI Nose-powered POCT are expected to be completed by the end of 2023, positioning Ainos to capitalize on the US$256 billion STI testing market.